AlloVir (ALVR) Stock Price, News & Analysis

Company Overview

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Key Stats

• Today's Range: $10.10 to $12.50
• 50-Day Range: $8.77 to $11.47
• 52-Week Range: $7.96 to $24.15
• Volume: 40,759 shs
• Average Volume: 16,714 shs
• Market Capitalization: $55.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AlloVir Stock Analysis - MarketRank™

AlloVir scored higher than 55% of companies evaluated by MarketBeat, and ranked 451st out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for AlloVir.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of AlloVir is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AlloVir is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

AlloVir has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.56% of the float of AlloVir has been sold short.

Short Interest Ratio / Days to Cover

AlloVir has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AlloVir has recently decreased by 8.82%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AlloVir does not currently pay a dividend.

Dividend Growth

AlloVir does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.56% of the float of AlloVir has been sold short.

Short Interest Ratio / Days to Cover

AlloVir has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AlloVir has recently decreased by 8.82%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

AlloVir has a news sentiment score of 1.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for AlloVir this week, compared to 0 articles on an average week.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, AlloVir insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,801.00 in company stock.

Percentage Held by Insiders

32.07% of the stock of AlloVir is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

66.05% of the stock of AlloVir is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALVR Stock Analysis - Frequently Asked Questions

How have ALVR shares performed this year?

AlloVir's stock was trading at $9.66 at the beginning of 2025. Since then, ALVR stock has increased by 13.9% and is now trading at $11.00.
View the best growth stocks for 2025 here.

How were AlloVir's earnings last quarter?

AlloVir, Inc. (NASDAQ:ALVR) released its quarterly earnings results on Wednesday, August, 14th. The company reported ($1.15) earnings per share for the quarter, topping analysts' consensus estimates of ($2.30) by $1.15.

When did AlloVir's stock split?

Shares of AlloVir reverse split before market open on Thursday, January 16th 2025. The 1-23 reverse split was announced on Wednesday, January 15th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 15th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did AlloVir IPO?

AlloVir (ALVR) raised $252 million in an IPO on Thursday, July 30th 2020. The company issued 14,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

Who are AlloVir's major shareholders?

AlloVir's top institutional shareholders include Gilead Sciences Inc. (330.72%), Octagon Capital Advisors LP (222.96%), Millennium Management LLC (60.31%) and Jacobs Levy Equity Management Inc. (13.21%). Insiders that own company stock include Gilead Sciences, Inc, Diana Brainard, Beek Jeroen B Van, Edward Miller, David Hallal, Brett R Hagen and Jeffrey S Bornstein.
View institutional ownership trends.

How do I buy shares of AlloVir?

Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AlloVir own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AlloVir investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AUO (AUOTY), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 3/24/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALVR
• CIK: 1754068
• Web: www.allovir.com
• Phone: 617-433-2605
• Fax: N/A
• Employees: 110
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($20.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-190,420,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -71.03%
• Return on Assets: -61.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 86.78
• Quick Ratio: 86.78

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $29.35 per share
• Price / Book: 0.37

Miscellaneous

• Outstanding Shares: 5,043,000
• Free Float: 3,425,000
• Market Cap: $55.47 million
• Optionable: Optionable
• Beta: 0.63